Serendipity and the discovery of novel compounds that restore mitochondrial plasticity.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and mechanistic discovery without primary clinical data
PubMed 25188726 · doi:10.1038/clpt.2014.174
What was done
This narrative review describes the discovery and mechanism of a class of compounds targeting cardiolipin on the inner mitochondrial membrane, focusing on SS-31, to improve electron transport chain efficiency and bioenergetics in aging and disease.
What was found
The abstract reports no numerical data. It qualitatively describes that these compounds optimize electron transport chain efficiency, restore ATP production and mitochondrial plasticity in aging and disease models, and have no reported effect on healthy organisms. It notes that SS-31 has entered clinical trials.
Why it matters
Targeting inner mitochondrial membrane cardiolipin represents a novel pharmacological strategy to restore cellular energy production in age-associated conditions.
Limits
This is a narrative review with no primary data, quantitative endpoints, or sample sizes provided in the abstract. Claims are based primarily on preclinical models and mechanistic rationale.
Cited by
- supports The peptide SS-31 was discovered by Hazel Szeto.